A Chinese institutional broker note highlights a 'four-way resonance' in AI-driven drug discovery, with major tech and pharma companies accelerating wet-lab validation, leading to strong stock performances.
AI4S is entering a new phase of large-scale wet-lab validation, creating investment opportunities in Chinese biotech supply chain and platform companies.
Free preview — more China A-share & HK research · About Us · Legal & Privacy